Pramlintide

Pramlintide (Symlin) is a relatively new adjunct for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. Pramlintide is delivered as an acetate salt.

Read more about Pramlintide:  Pharmacology, Approval, Design and Structure